Amendment to the Product Development, Option, License and Commercialization AgreementCommercialization Agreement • March 21st, 2016 • Cellectis S.A. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 21st, 2016 Company IndustryThis Amendment to the Product Development, Option, License and Commercialization Agreement shall become effective as of the 18th of November 2015 (hereinafter the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having a principal place of business at 50 rue Carnot, 92150 Suresnes, France (“LLS”) and lnstitut de Recherches lnternationales Servier, a corporation incorporated under the laws of France having its principal place of business at 50 rue Carnot, 92 150 Suresnes, France (“IRIS”) (LLS and IRIS being together referred to as “Servier”), and Cellectis SA, a company incorporated under the laws of France having a principal place of business, at 8, rue de la Croix Jarry, 75013 Paris, France (“Cellectis”). Cellectis and Servier are individually referred to herein as a “Party” and collectively, as the “Parties.”